Bristol Myers Squibb

Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data
Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data
BioPharma Dive
Takeda
Bristol Myers Squibb
clinical trials
TAK-279
plaque psoriasis
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Bristol Myers meets some diversity goals early, while missing others
Bristol Myers meets some diversity goals early, while missing others
Endpoints
Bristol Myers Squibb
diversity
clinical trials
clinical trial diversity
Flag link:
Bristol Myers blasts off with SpaceX to study biomanufacturing in space
Bristol Myers blasts off with SpaceX to study biomanufacturing in space
Endpoints
Bristol Myers Squibb
SpaceX
Flag link:
Exscientia builds cancer pipeline with two BMS drugs
Exscientia builds cancer pipeline with two BMS drugs
Pharmaphorum
Exscientia
Bristol Myers Squibb
oncology
EXS73565
EXS74539
Flag link:
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Flag link:
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Endpoints
Bristol Myers Squibb
Germany
Opdivo
Opdualag
Flag link:
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Fierce Pharma
Bristol Myers Squibb
Breyanzi
Celgene
legal
M&A
CVRs
Flag link:
Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients
Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients
BioPharma Dive
Bristol Myers Squibb
JNJ
clinical trials
Librexia
bloodthinners
Flag link:
New Report Reveals Pharmaceutical Industry Social Media Pioneers
New Report Reveals Pharmaceutical Industry Social Media Pioneers
LBB Online
Ogilvy Health
social media
Bristol Myers Squibb
Boehringer Ingelheim
Roche
Flag link:
Bristol Myers expands footprint in India with drug development and IT center
Bristol Myers expands footprint in India with drug development and IT center
Endpoints
Bristol Myers Squibb
India
drug development
IT
Flag link:
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Flag link:
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Fierce Pharma
Bristol Myers Squibb
Abecma
CAR-T
Multiple Myeloma
Flag link:
BMS returns $475M IL-12 oncology asset to Dragonfly’s pond
BMS returns $475M IL-12 oncology asset to Dragonfly’s pond
Fierce Biotech
Dragonfly Therapeutics
Bristol Myers Squibb
oncology
DF6002
solid tumors
Flag link:
Q4 earnings roundup: Merck, Lilly, Takeda and BMS release financials
Q4 earnings roundup: Merck, Lilly, Takeda and BMS release financials
Medical Marketing and Media
earnings
Merck
Takeda
Bristol Myers Squibb
Eli Lilly
Flag link:
Amgen commits $8m to improve clinical trial diversity
Amgen commits $8m to improve clinical trial diversity
Outsourcing Pharma
Amgen
clinical trials
clinical trial diversity
Bristol Myers Squibb
Winn Award
Flag link:
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Endpoints
Bristol Myers Squibb
CAR-T
Breyanzi
CLL
cell therapy
Flag link:
BMS settles lawsuit with two fired employees who refused COVID vaccines
BMS settles lawsuit with two fired employees who refused COVID vaccines
Fierce Pharma
Bristol Myers Squibb
legal
COVID-19
vaccines
Flag link:

Pages